Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Be Well Clinical Studies LLC

Neither a doctor nor a teaching hospital

Research payments

$4,815,032

1,563 payments

Through program year 2025, Be Well Clinical Studies LLC is reported as receiving $4,815,032 in research payments, across 1,563 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $916,130 121
2024 Research $1,618,785 122
2023 Research $1,895,406 1,280
2022 Research $360,787 38
2021 Research $23,924 2

Breakdown

Who paid Research payments · program years 2021–2025
  1. Moderna TX, Inc. $2,048,176 1,344 payments
  2. Sanofi Pasteur Inc. $1,103,888 105 payments
  3. Novavax Inc $349,542 41 payments
  4. Sanofi US Services Inc. $279,042 12 payments
  5. Vertex Pharmaceuticals Incorporated $260,756 2 payments
  6. Janssen Research & Development, LLC $248,541 15 payments
  7. Eli Lilly and Company $187,541 3 payments
  8. GlaxoSmithKline, LLC. $153,398 33 payments
  9. Amgen Inc. $130,430 1 payment
  10. ITI, Inc. $29,000 4 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts $568,426 31 payments
  2. Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) $519,009 30 payments
  3. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $401,695 368 payments
  4. A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age $397,225 691 payments
  5. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $392,131 36 payments
  6. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $260,980 170 payments
  7. A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy $260,756 2 payments
  8. A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years $248,541 15 payments
  9. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age $241,861 13 payments
  10. A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). $190,297 32 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record